<DOC>
	<DOCNO>NCT02069496</DOCNO>
	<brief_summary>This post-marketing surveillance study design collect safety information post-vaccination adverse event adverse reaction recipient Arepanrix® ( H1N1 ) Intramuscular Injection . The following item investigate priority investigation item . &lt; Priority investigation item &gt; 1 . Allergic reactions 2 . Anaphylaxis</brief_summary>
	<brief_title>Drug Use Investigation Arepanrix® ( H1N1 )</brief_title>
	<detailed_description />
	<criteria>Subjects receive Arepanrix® intramuscular injection first time</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>